EPIX STOCK NEWS: EPIX Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Essa Pharma Inc.

Core Viewpoint - A class action has been filed against ESSA Pharma Inc. for allegedly misleading investors about the efficacy of its drug candidate masofaniten, particularly in its combination with enzalutamide for treating prostate cancer [1][2]. Group 1: Allegations and Findings - The complaint alleges that ESSA failed to disclose that masofaniten combined with enzalutamide showed no clear efficacy benefit over enzalutamide alone [2]. - It is claimed that the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, indicating that the company overstated masofaniten's clinical and commercial prospects [2]. - On October 31, 2024, ESSA announced the termination of Phase 2 of the M-E Combination Study, citing a higher rate of PSA90 response in patients treated with enzalutamide alone and no clear efficacy benefit from the combination [3]. Group 2: Market Impact - Following the announcement of the study termination, ESSA's stock price fell by $3.80 per share, a decrease of 73.08%, closing at $1.40 per share on November 1, 2024 [3]. Group 3: Class Action Participation - Investors may be eligible to participate in the class action against ESSA Pharma Inc., with options to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for participation [5].